Analysts at Jefferies Group (NYSE: JEF) started coverage on shares of Ironwood Pharmaceuti (NASDAQ: IRWD) in a research report issued to clients and investors on Monday. The firm set a “hold” rating on the stock.
Several other analysts have also recently commented on the stock. Analysts at UBS AG (NYSE: UBS) initiated coverage on shares of Ironwood Pharmaceuti in a research note to investors on Thursday, April 12nd. They set a “neutral” rating and a $14.00 price target on the stock. Separately, analysts at Wedbush downgraded shares of Ironwood Pharmaceuti from an “outperform” rating to an “underperform” rating in a research note to investors on Monday, March 5th. Finally, analysts at Cantor Fitzgerald downgraded shares of Ironwood Pharmaceuti from a “hold” rating to a “sell” rating in a research note to investors on Wednesday, February 29th. They now have a $10.00 price target on the stock.
Ironwood Pharmaceuti traded down 3.71% on Monday, hitting $12.71. Ironwood Pharmaceuti has a 1-year low of $9.97 and a 1-year high of $16.50. The company’s market cap is $1.319 billion.
Ironwood Pharmaceuti last issued its quarterly earnings data on Tuesday, May 1st. The company reported ($0.34) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.23) by $0.11. The company’s quarterly revenue was up 19.6% on a year-over-year basis. On average, analysts predict that Ironwood Pharmaceuti will post $0.10 earnings per share next quarter.
Ironwood Pharmaceuticals, Inc., formerly Microbia, Inc. is an entrepreneurial pharmaceutical company that discovers, develops and focuses to commercialize medicines targeting important therapeutic needs.